TNDM
NasdaqTANDEM DIABETES CARE INC
Technology · Surgical & Medical Instruments & Apparatus
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
🔒 price chart needs market-data feed$702.8M
2021
$801.2M
2022
$747.7M
2023
$940.2M
2024
$1.0B
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$1.0B
Net Income$-204.7M
Gross Profit$546.0M
Oper Income$-187.3M
EPS (dil)$-3.04
Rev/sh$14.81
FCF/sh$-0.43
Book/sh$2.26
Gross M53.8%
Oper M-18.5%
Profit M-20.2%
FCF M-2.9%
ROE-131.9%
ROA-23.2%
ROIC-46.1%
R&D/Rev9.1%
Rev Y/Y7.9%
Rev 3Y CAGR8.2%
EPS Y/Y-106.8%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y+2.8%
Current Ratio2.55
Quick Ratio2.02
Debt/Eq2.26
Int Coverage-23.7×
Net Debt$260.1M
Total Debt$350.7M
Cash & Eq$90.6M
Total Assets$881.1M
Oper CF$-9.7M
Capex$19.9M
Free CF$-29.7M
Buybacks$0
Equity$155.2M
Liabilities$725.9M
Shs Outstand0.07B
SectorTechnology
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $702.8M | $801.2M | $747.7M | $940.2M | $1.0B |
| Gross Profit | $376.2M | $413.0M | $367.7M | $489.6M | $546.0M |
| Operating Income | $22.7M | $-92.8M | $-233.2M | $-99.1M | $-187.3M |
| Net Income | $15.6M | $-94.6M | $-222.6M | $-96.0M | $-204.7M |
| Diluted EPS | $0.24 | $-1.47 | $-3.43 | $-1.47 | $-3.04 |
| Operating Cash Flow | $111.4M | $50.5M | $-31.8M | $24.2M | $-9.7M |
| Free Cash Flow | $97.2M | $16.4M | $-58.6M | $5.0M | $-29.7M |
COMMUNITY · $TNDM0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.